In the SURMOUNT-1 trial, tirzepatide not only produced substantial and sustained weight loss over 176 weeks in individuals with obesity and prediabetes, but also significantly delayed the onset of type 2 diabetes compared to placebo
The risk of lean mass loss with fasting and how to mitigate it [47:15]
Enhanced fat loss especially visceral fat Increased lean muscle mass Improved strength and exercise capacity Better sleep quality and deeper REM cycles Enhanced recovery from training Dosage1.2mg/mL (CJC-1295) + 2mg/mL (Ipamorelin), 5mL vial AdministrationSubcutaneous injection, evening About What is CJC-1295/Ipamorelin
The structural reason the good and the bad arrive together Tirzepatides second receptor, GIP, buffers some nausea
However, with chronic exposure, the body may begin to blunt its pulsatility
Some pointed to evidence suggesting that not everyone diagnosed with obesity needs to lose weight to stay healthy and bemoaned the use of BMI, a controversial measure that is increasingly considered inadequate unless additional factors such as waist circumference are also evaluated